

# Female Sexual Pain Disorders

Evaluation and Management

Second Edition

Editors

Andrew T. Goldstein, Caroline F. Pukall, Irwin Goldstein

Associate Editors

Jill M. Krapf, Sue W. Goldstein, Gail Goldstein



WILEY Blackwell

# Table of Contents

[Cover](#)

[Title Page](#)

[Copyright Page](#)

[List of contributors](#)

[1 Nosology of Pelvic Pain and Vulvodynia](#)

[1.1 Introduction](#)

[1.2 Chronic Pelvic Pain Nosology](#)

[1.3 Bladder Pain Syndrome](#)

[1.4 Nosology of Sexual Pain](#)

[1.5 Other Definitions of Vulvar Pain](#)

[1.6 Conclusion](#)

[References](#)

[2 The Prevalence and Relevance of Vulvodynia](#)

[2.1 Introduction](#)

[2.2 Prevalence](#)

[2.3 Comorbid Conditions](#)

[2.4 Relevance to the Individual Woman, Family, and Society](#)

[2.5 Multidisciplinary Treatment](#)

[2.6 Recommendations](#)

[2.7 Conclusion](#)

[References](#)

[3 Pathophysiology of Pain](#)

[3.1 Introduction](#)

[3.2 Nociception or Pain?](#)

[3.3 Basics of Nociception](#)

[3.4 Hormone Regulation](#)

[3.5 Somatic and Visceral Pain](#)

[3.6 Referred Pain](#)

[3.7 Inflammation](#)

[3.8 Peripheral and Central Sensitization](#)

[3.9 The Brain](#)

[3.10 Summary](#)

[References](#)

[4 The Role of Inflammation in Vulvodynia](#)

[4.1 Introduction](#)

[4.2 A Review of the Evolving Research into the Inflammatory Pathogenesis of Vulvodynia](#)

[4.3 A Theoretical Model of Vulvodynia Etiopathogenesis](#)

[References](#)

[5 Neuroproliferative Processes in Vulvodynia](#)

[5.1 Introduction](#)

[5.2 Mast Cells and Hyperinnervation](#)

[5.3 Genetic Predisposition to Neuroproliferation and Allodynia](#)

[5.4 Animal Models Support the Evidence of Neuroproliferation in Vestibulodynia](#)

[5.5 Discussion](#)

[References](#)

[6 Pelvic Floor Muscle Dysfunction and Structural Processes in Vulvodynia](#)

[6.1 Introduction](#)

[6.2 Anatomy and Function of the Pelvis](#)

[6.3 Disorders of the Symphysis Pubis](#)

[6.4 Hip Disorders](#)

[6.5 Pelvic Obliquity](#)

[6.6 Sacroiliac Joint Disorders](#)

[6.7 Coccydynia](#)

[6.8 Abdominal Wall/Anterior Pelvic Pain](#)

[6.9 Piriformis/Buttock Pain](#)

[6.10 Lumbar Spine Disorders](#)

[6.11 Pudendal Neuralgia](#)

[6.12 Conclusion](#)

[References](#)

[7 Hormonal Causes of Dyspareunia](#)

[7.1 Introduction](#)

[7.2 Combined Hormonal Contraceptives](#)

[7.3 Spironolactone](#)

[7.4 Hormonal Therapy for Breast Cancer](#)

[References](#)

[8 Genetic Factors in Vulvodynia](#)

[References](#)

[9 Central Factors in Vulvodynia](#)

[9.1 Introduction](#)

[9.2 Central Mechanisms in Vulvodynia](#)

[References](#)

[10 Comorbidities of Vulvodynia](#)

[10.1 Introduction](#)

[10.2 Comorbid Conditions](#)

[10.3 Mechanism of Comorbidity](#)

[10.4 Implications for Treatment and Effect on Outcomes](#)

## References

### 11 Psychosocial Factors in Vulvodynia

#### 11.1 Introduction

#### 11.2 Preview of our Interpersonal Emotion Regulation Model

#### 11.3 Distal and Proximal Interpersonal Factors in Vulvodynia

#### 11.4 Conclusions

## References

### 12 Pain Assessment in Vulvodynia

#### 12.1 Introduction

#### 12.2 Setting Up a Validating Context

#### 12.3 General Information to Gather

#### 12.4 Pain-specific Assessment

#### 12.5 Conclusions

## References

### 13 Pain Assessment in Vulvodynia

#### 13.1 Introduction

#### 13.2 Objective Measures Focusing on the Vestibule

#### 13.3 Objective Measures Focusing on the Pelvic Floor

#### 13.4 Tools and Instruments to Assess PFM Involvement

#### 13.5 Conclusions

## References

### 14 An Overview of the Evaluation of Dyspareunia, Vulvovaginal Pain, and Pelvic Pain

#### 14.1 Introduction

#### 14.2 Evaluation

### [14.3 Summary](#)

#### [References](#)

## [15 Vulvoscopic Evaluation of Vulvodynia](#)

### [15.1 Introduction](#)

### [15.2 Equipment and Setup](#)

### [15.3 Steps of Vulvoscopy/ Vulvoscopy Standard Operating Procedure](#)

### [15.4 Use of Acetic Acid](#)

### [15.5 Research and Future Directions](#)

### [15.6 Summary of Vulvoscopy Steps](#)

#### [References](#)

## [16 Pelvic Floor Assessment of Vulvodynia](#)

### [16.1 Introduction](#)

### [16.2 Pelvic Floor Anatomy and Physiology](#)

### [16.3 Patient History](#)

### [16.4 Physical Therapy Examination](#)

### [16.5 Physical Therapy Assessment and Treatment Plan](#)

### [16.6 Assessment and Treatment](#)

### [16.7 Evidence for Physical Therapy Treatment](#)

### [16.8 Conclusion](#)

#### [References](#)

## [17 Psychosocial Assessment of Vulvodynia](#)

### [17.1 Introduction](#)

### [17.2 Consequences of Vulvodynia or Associated Difficulties](#)

### [17.3 Overview of Presenting Problem](#)

### [17.4 Cognitive, Affective, Behavioral, and Relational Contributors](#)

[17.5 Exploring the Past: Childhood Victimization](#)

[17.6 Conclusions](#)

[References](#)

[18 Neurological Assessment in Genito-pelvic Pain](#)

[18.1 Introduction](#)

[18.2 Vibration Perception Threshold Testing](#)

[18.3 Cold and Warm Temperature Perception Threshold Testing](#)

[18.4 Sacral Dermatome Testing](#)

[18.5 Bulbocavernosus Reflex Latency Testing](#)

[18.6 Pathologies of Genito-pelvic Pain](#)

[References](#)

[19 Diagnostic and Treatment Algorithm for Women with Vulvodynia and Sexual Pain Disorders](#)

[19.1 Introduction](#)

[19.2 The Diagnostic Algorithm](#)

[20 Medical Treatment of Inflammatory-associated Provoked Vestibulodynia](#)

[20.1 Introduction](#)

[20.2 Patient History and Clinical Presentation](#)

[20.3 Inflammation: Pathophysiology and Basic Science Research](#)

[20.4 Treatment of IPVD](#)

[20.5 Conclusion](#)

[References](#)

[21 Treatment of Neuroproliferative-associated Provoked Vestibulodynia with Topical Medications](#)

[21.1 Introduction](#)

[21.2 Lidocaine](#)

[21.3 Amitriptyline](#)

[21.4 Gabapentin](#)

[21.5 Capsaicin](#)

[21.6 Ketamine](#)

[21.7 Treatment Recommendations](#)

[21.8 Conclusions](#)

[References](#)

## [22 Hormonal Factors in Women's Sexual Pain Disorders](#)

[22.1 Introduction](#)

[22.2 Sex Steroid Androgens and Estrogens: Physiology](#)

[22.3 Menopause: Androgen and Estrogen Deficiency](#)

[22.4 Premenopause and Androgen Deficiency](#)

[22.5 Hormonally Mediated Vestibulodynia](#)

[22.6 Conclusion](#)

[References](#)

## [23 Physical Therapy Treatment of Pelvic Floor Dysfunction](#)

[23.1 Introduction](#)

[23.2 Manual Therapy Techniques](#)

[23.3 Therapeutic Exercise](#)

[23.4 Conclusion](#)

[References](#)

## [24 Treatment of Vulvodynia with Pelvic Floor Muscle Relaxants/Injections](#)

[24.1 Introduction](#)

[24.2 Trigger Point Injections](#)

[24.3 Pelvic Nerve Blocks](#)



[24.4 Injection Agents](#)

[24.5 Conclusion](#)

[References](#)

[25 Psychosocial Treatments for Vulvodynia](#)

[25.1 Introduction](#)

[25.2 Psychosocial Treatments: Empirical Evidence](#)

[25.3 Therapy Phases and Process](#)

[25.4 Common Therapeutic Issues and Counter-Indications](#)

[25.5 Conclusions](#)

[References](#)

[26 Complementary and Integrative Health Approaches for the Treatment of Vulvodynia](#)

[26.1 Introduction](#)

[26.2 Acupuncture and Traditional Chinese Medicine](#)

[26.3 Transcutaneous Electrical Nerve Stimulation](#)

[26.4 Transcranial Direct Current Stimulation](#)

[26.5 Vaginal Dilators](#)

[26.6 Conclusions](#)

[References](#)

[27 Vulvar Vestibulectomy](#)

[27.1 Introduction](#)

[27.2 Histopathological Rationale for Surgery](#)

[27.3 Types of Surgical Treatment](#)

[27.4 Surgical Technique](#)

[27.5 Assessing Outcomes for Surgical Therapy](#)

[27.6 Conclusions and Directions for the Future](#)

[References](#)

## 28 Vulvovaginitis

28.1 Vaginitis and Dyspareunia

28.2 Bacterial Vaginosis

28.3 Trichomoniasis

28.4 Vulvovaginal Candidiasis

28.5 Desquamative Inflammatory Vaginitis

References

## 29 Vulvar Dermatoses as a Cause of Dyspareunia

29.1 Introduction

29.2 Physical Examination

29.3 The Vulvar Dermatoses

29.4 Summary

References

## 30 Genitourinary Syndrome of Menopause: the Role of Estrogens and Androgens

30.1 Introduction

30.2 Epidemiology

30.3 Diagnosis

30.4 Treatment

30.5 Conclusion

References

## 31 Female Genital Cutting

31.1 Introduction

31.2 Types of FGC

31.3 Epidemiology

31.4 Sequelae of FGC

31.5 Surgical Management

31.6 Culturally Competent Care

## [31.7 Conclusions](#)

### [References](#)

## [32 Interstitial Cystitis/Bladder Pain Syndrome](#)

### [32.1 Definition of Interstitial Cystitis/Bladder Pain Syndrome](#)

### [32.2 Prevalence](#)

### [32.3 Associated Comorbidities](#)

### [32.4 Etiology](#)

### [32.5 Assessment](#)

### [32.6 Treatment of Hunner Lesion Interstitial Cystitis](#)

### [32.7 Treatment of Non-Hunner Lesion IC/BPS](#)

### [32.8 Investigational Treatments](#)

### [32.9 Conclusion](#)

### [References](#)

## [33 The Basic Science of Endometriosis](#)

### [33.1 Introduction](#)

### [33.2 Etiology and Pathophysiology](#)

### [33.3 Risk Factors and Genetics](#)

### [33.4 Clinical Presentation \[1\]](#)

### [33.5 Physical Examination and Imaging](#)

### [33.6 Diagnosis](#)

### [33.7 Treatment](#)

### [33.8 Sexual Implications](#)

### [33.9 Personalized Treatment for Endometriosis-associated Deep Dyspareunia?](#)

### [33.10 Conclusion](#)

### [References](#)

## [34 Endometriosis Treatment](#)

[34.1 Endometriosis](#)

[34.2 Diagnosis](#)

[34.3 Medical Therapy](#)

[34.4 Surgical Management](#)

[34.5 Conclusion](#)

[References](#)

[35 Chronic Pelvic Pain](#)

[35.1 Introduction](#)

[35.2 Epidemiology](#)

[35.3 Causes and Underlying Mechanisms](#)

[35.4 Diagnosis](#)

[35.5 Treatment](#)

[35.6 Conclusion](#)

[References](#)

[36 Postpartum Genito-pelvic Pain](#)

[36.1 Introduction](#)

[36.2 Definition](#)

[36.3 Epidemiology](#)

[36.4 Clinical Presentation](#)

[36.5 Etiology and Risk Factors](#)

[36.6 Physical and Psychosocial Impacts](#)

[36.7 Evaluation](#)

[36.8 Management](#)

[36.9 Prevention](#)

[36.10 Conclusion](#)

[References](#)

[37 Pudendal Neuralgia](#)

[37.1 Introduction](#)

[37.2 Anatomy](#)

[37.3 Risk Factors and Potential Etiologies](#)

[37.4 Symptoms](#)

[37.5 Diagnosis](#)

[37.6 Treatment](#)

[37.7 Conclusion](#)

[References](#)

## [38 Cancer and Genito-pelvic Pain](#)

[38.1 Introduction](#)

[38.2 Sexual Dysfunction After Specific Cancer Treatments](#)

[38.3 Pretreatment Counseling](#)

[38.4 Evaluation of Women with Sexual Dysfunction After Cancer Treatment](#)

[38.5 Sexual Pain in Women Affected by Cancer](#)

[38.6 Prevention of Sexual Dysfunction During Treatment for Cancer](#)

[38.7 Cultural Considerations](#)

[38.8 Conclusion](#)

[References](#)

## [39 Irritable Bowel Syndrome and Female Sexual Dysfunction](#)

[39.1 Introduction](#)

[39.2 Irritable Bowel Syndrome](#)

[39.3 Comorbid Conditions and Symptoms in IBS](#)

[39.4 Conclusion](#)

[Acknowledgments](#)

[References](#)

## 40 Inability to Experience Penetrative Vaginal Intercourse

### 40.1 Introduction

### 40.2 Prevalence

### 40.3 Etiology

### 40.4 The Fear-Avoidance Model

### 40.5 Assessment

### 40.6 Treatment

### 40.7 Motivation for Treatment

### 40.8 Summary

### References

## 41 Chronic Clitoral Pain and Clitorodynia

### 41.1 Introduction

### 41.2 Clitoral Innervation

### 41.3 Secondary Chronic Clitoral Pain

### 41.4 Diagnostic Work-up for Clitorodynia

### 41.5 Clitorodynia

### 41.6 Summary

### References

## 42 Generalized Unprovoked Vulvodynia

### 42.1 Introduction

### 42.2 Etiology and Associated Factors

### 42.3 Diagnosis, History and Examination

### 42.4 Prevalence and Epidemiological Characteristics

### 42.5 Treatments and Interventions

### 42.6 Summary

### References

## 43 Persistent Genital Arousal Disorder

[43.1 Introduction](#)

[43.2 Prevalence and Sex Distribution](#)

[43.3 Symptom Characteristics](#)

[43.4 Distress](#)

[43.5 Psychosocial Impact](#)

[43.6 Healthcare Experiences](#)

[43.7 Etiological Factors](#)

[43.8 Assessment and Treatment](#)

[43.9 Conclusion](#)

[References](#)

[44 Fibromyalgia and Female Sexual Pain Disorders](#)

[44.1 Introduction](#)

[44.2 Fibromyalgia](#)

[44.3 Female Sexual Pain Disorders](#)

[44.4 Fibromyalgia, Female Sexual Pain Disorders,  
and Female Sexual Dysfunction](#)

[44.5 Fibromyalgia Treatments](#)

[44.6 Summary](#)

[References](#)

[45 Animal Models of Genito-pelvic Pain](#)

[45.1 Introduction](#)

[45.2 Uropelvic Pain](#)

[45.3 Pelvic Pain](#)

[45.4 Vulvovaginal Pain](#)

[Summary](#)

[References](#)

[46 Patient Advocacy for Vulvodynia](#)

[46.1 Introduction](#)

[46.2 Raising Awareness](#)

[46.3 NIH Vulvodynia Conferences](#)

[46.4 NVA-funded Research and Clinics](#)

[46.5 NVA Lobbying on Capitol Hill](#)

[46.6 NVA's CME/CE-accredited Vulvodynia Tutorial](#)

[46.7 International Outreach](#)

[46.8 NVA Patient and Professional Membership](#)

[References](#)

[47 Practical Aspects of Establishing a Vulvovaginal Pain Center](#)

[47.1 Introduction](#)

[47.2 Communication with Patient](#)

[47.3 Physical Layout](#)

[47.4 Communication and Confidentiality among Providers](#)

[47.5 Financial Success](#)

[47.6 Conclusion](#)

[References](#)

[48 Editors' Wish List](#)

[48.1 Andrew Goldstein](#)

[48.2 Caroline Pukall](#)

[48.3 Irwin Goldstein](#)

[References](#)

[Index](#)

[End User License Agreement](#)

## **List of Tables**

Chapter 1



[Table 1.1 The 2015 ISSVD, ISSWSH, IPPS vulvar pain and vulvodynia nomenclatur...](#)

## Chapter 4

[Table 4.1 Several important history and physical examination clues to help gu...](#)

[Table 4.2 Induction of neuroinflammation can arise from multiple sources, inc...](#)

## Chapter 5

[Table 5.1 Nerve fiber proliferation \(NFP\) in localized provoked vulvodynia.](#)

## Chapter 7

[Table 7.1 Studies showing a relationship between combined hormonal contracept...](#)

## Chapter 8

[Table 8.1 Gene polymorphisms that have been associated with vulvodynia.](#)

## Chapter 13

[Table 13.1 Typical QST devices and methods used in vulvodynia research and th...](#)

## Chapter 14

[Table 14.1 Useful questions when obtaining a sexual pain history.](#)

## Chapter 16

[Table 16.1 Common symptoms of hypertonic pelvic floor muscles.](#)

[Table 16.2 Possible causes of pelvic floor musculoskeletal dysfunction.](#)

[Table 16.3 External physical therapy physical examination for pelvic pain.](#)

[Table 16.4 Physical therapy treatment options.](#)

## Chapter 18

[Table 18.1 Neurogenital testing used to determine location of pathology of ge...](#)

## Chapter 20

[Table 20.1 Vulvar allergens.](#)

## Chapter 21

[Table 21.1 Clinical trials of topical treatment in provoked vestibulodynia.](#)

## Chapter 28

[Table 28.1 Differential diagnosis of vulvovaginitis.](#)

[Table 28.2 Complications of bacterial vaginosis.](#)

[Table 28.3 Therapy for vaginal candidiasis.](#)

## Chapter 29

[Table 29.1 Allergen class.](#)

## Chapter 30

[Table 30.1 Signs and symptoms of GSM.](#)

[Table 30.2 Pharmacological treatments for GSM.](#)

## Chapter 31

[Table 31.1 2016 WHO classification of FGC.](#)

## Chapter 33

[Table 33.1 Proposed classification of deep dyspareunia in endometriosis.](#)

## Chapter 35

[Table 35.1 Standard dosages for commonly used neuromodulator treatments for C...](#)

## Chapter 37

[Table 37.1 Nantes criteria for pudendal nerve entrapment \(PNE\), a subcategory...](#)

## Chapter 38

[Table 38.1 Most common biological causes of sexual pain disorders in women af...](#)

## Chapter 39

[Table 39.1 Rome III diagnostic criteria for IBS.](#)

[Table 39.2 Reported rates of dyspareunia and sexual dysfunction in women with...](#)

## Chapter 43

[Table 43.1 Topics to include in a psychosocial assessment.](#)

## Chapter 44

[Table 44.1 The American College of Rheumatology diagnostic criteria for fibro...](#)

## Chapter 45

[Table 45.1 Overview of animal models of genito-pelvic pain.](#)

## Chapter 47

[Table 47.1 Coding for sexual pain and related disorders.](#)

# List of Illustrations

## Chapter 3

[Figure 3.1 Abdominopelvic pain referral patterns supported by clinical and r...](#)

[Figure 3.2 Abdominopelvic pain referral patterns that reflect somatic versus...](#)

[Figure 3.3 Abdominopelvic pain referral patterns that could be explained by ...](#)

## Chapter 4

[Figure 4.1 A proposed natural history of vulvodynia development.](#)

## Chapter 5

[Figure 5.1 PGP 9.5 stain in a specimen from a woman with vestibulodynia show...](#)

[Figure 5.2 Giemsa stain in a specimen from a woman with vestibulodynia showi...](#)

[Figure 5.3 CD117 \(c-KIT\) stain in a specimen from a woman with vestibulodyni...](#)

[Figure 5.4 Heparanase expression in a specimen from a woman with vestibulody...](#)

## Chapter 6

[Figure 6.1 Manual palpation of the pubic symphysis joint which is asymmetric...](#)

[Figure 6.2 External palpation of a coccyx which is hyperflexed or in a chron...](#)

## Chapter 9

[Figure 9.1 \(a\) Graphic illustration of female lower genital tract showing ex...](#)

## Chapter 14

[Figure 14.1 Erythema of the ostia of the Bartholin gland in a patient with h...](#)

[Figure 14.2 Vulvar lichen sclerosus. Changes seen include complete resorptio...](#)

[Figure 14.3 Cotton-swab test of the vulvar vestibule.](#)

## Chapter 15

[Figure 15.1 Standard vulvoscope setup: a colposcope on a rolling floor-mount...](#)

[Figure 15.2 A Mayo stand is set up prior to the start of vulvoscopy with the...](#)

[Figure 15.3 Example standardized form used by a medical assistant during a v...](#)

[Figure 15.4 Width of the labia minora is documented by extending the labia o...](#)

[Figure 15.5 Resorption can be quantified by estimating what percentage, if a...](#)

[Figure 15.6 Magnified view of the clitoris during vulvosopic examination. N...](#)

[Figure 15.7 Vulvosopic view of vestibule and minor vestibular glands: moist...](#)

[Figure 15.8 Speculum examination: speculum is rotated 90° to allow visualiza...](#)

## Chapter 16

[Figure 16.1 \(a\) Superficial muscles of the urogenital diaphragm. \(b\) Deep mu...](#)

[Figure 16.2 Peripheral pelvic nerves.](#)

[Figure 16.3 Pudental nerve branches.](#)

## Chapter 18

[Figure 18.1 Biothesiometer.](#)

[Figure 18.2 Regions of neurological pathophysiologies, from the genitals to ...](#)

## Chapter 19

[Figure 19.1 Vulvodynia and vulvar pain diagnostic algorithm.](#)

## Chapter 24

[Figure 24.1 The pudendal nerve trunk wraps around the base of the ischial sp...](#)

## Chapter 26

[Figure 26.1 Acupuncture protocol for the treatment of vulvodynia.](#)

[Figure 26.2 TENS delivered intravaginally through the PERIPROBE® VAG2ST...](#)

[Figure 26.3 Transcranial direct current stimulation \(tDCS\) with scalp electr...](#)

[Figure 26.4 Vaginal dilators of increasing gradation with inserter.](#)

## Chapter 27

[Figure 27.1 The entire vulvar vestibule is outlined with a marker pen.](#)

[Figure 27.2 The vestibular mucosa is excised.](#)

[Figure 27.3 The vaginal advancement flap is anchored in an advanced position...](#)

[Figure 27.4 The vaginal advancement flap is approximated to the perineum.](#)

## Chapter 28

[Figure 28.1 Microscopic findings in DIV. This wet mount shows high number of...](#)

## Chapter 29

[Figure 29.1 Scarring of lichen sclerosus.](#)

[Figure 29.2 Histopathological changes of lichen sclerosus.](#)

[Figure 29.3 Lichen sclerosus and squamous carcinoma.](#)

[Figure 29.4 Erosive lichen planus.](#)

[Figure 29.5 Contact dermatitis of the vulva.](#)

[Figure 29.6 Lichen simplex chronicus.](#)

[Figure 29.7 Aphthous ulcers.](#)

[Figure 29.8 Plasma cell vulvitis.](#)

## Chapter 30

[Figure 30.1 \(a\) Premenopausal normal vulva and \(b\) patient with severe genit...](#)

## Chapter 31

[Figure 31.1 Type III female genital cutting\\_\(FGC\), also known as infibulatio...](#)

[Figure 31.2 Prior to anterior vertical incision to expose the introitus and ...](#)

[Figure 31.3 Care should be exercised to avoid injury to the clitoral tissue....](#)

[Figure 31.4 The raw edges of the labia majora are then reapproximated with a...](#)

## Chapter 33

[Figure 33.1 Apex of the vagina: anatomical sites at the apex of the vagina t...](#)

[Figure 33.2 Sagittal view of the vaginal apex: anatomical sites at the apex ...](#)

[Figure 33.3 Underlying mechanisms for tenderness at anatomical sites at the ...](#)

## Chapter 37

[Figure 37.1 Hemipelvis view of the anatomy of the path of the pudendal nerve...](#)

[Figure 37.2 Example of vascular entrapment in the interligamentous space wit...](#)

[Figure 37.3 The peripheral nerve distributions can vary due to the course of...](#)

[Figure 37.4 Treatment pyramid. CBT, cognitive behavioral therapy; PFD, pelvi...](#)

## Chapter 38

[Figure 38.1 Percentage of female cancer survivors in the United States by co...](#)

## Chapter 40

[Figure 40.1 Fear avoidance model.](#)

## Chapter 41

[Figure 41.1 Keratin pearl \(KP\) adjacent to the glans clitoris.](#)



# **Female Sexual Pain Disorders**

## **Evaluation and Management**

Second Edition

Edited by

**Andrew T. Goldstein**

*George Washington University School of Medicine  
Washington, DC, USA*

**Caroline Pukall**

*Queen's University  
Kingston, Ontario, Canada*

**Irwin L. Goldstein**

*Alvarado Hospital  
San Diego, CA, USA*

Associate Editors

**Jill M. Krapf**

*George Washington University School of Medicine  
Washington, DC, USA*

**Sue W. Goldstein**

*San Diego Sexual Medicine  
San Diego, CA, US*

**Gail Goldstein**

*Annapolis Dermatology Center  
Annapolis, MD, USA*

**WILEY Blackwell**

This edition first published copyright year  
© copyright year John Wiley & Sons Ltd.

*Edition History*

John Wiley & Sons (1e, 2009)

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

The right of Andrew Goldstein, Caroline Pukall, and Irwin L. Goldstein to be identified as the author(s) of the editorial material in this work has been asserted in accordance with law.

*Registered Office(s)*

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA  
John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

*Editorial Office*

9600 Garsington Road, Oxford, OX4 2DQ, UK

For details of our global editorial offices, customer services, and more information about Wiley products visit us at [www.wiley.com](http://www.wiley.com).

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

*Limit of Liability/Disclaimer of Warranty*

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting scientific method, diagnosis, or treatment by physicians for any particular patient. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with

the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

*Library of Congress Cataloging-in-Publication Data*

Names: Goldstein T., Andrew, M.D., editor. | Pukall, Caroline F., editor. | Goldstein, Irwin, editor.

Title: Female sexual pain disorders : evaluation and management / edited by Andrew T. Goldstein, Caroline F. Pukall, Irwin Goldstein.

Description: Second edition. | Hoboken, NJ : Wiley-Blackwell, 2021. | Includes bibliographical references and index.

Identifiers: LCCN 2020024749 (print) | LCCN 2020024750 (ebook) | ISBN 9781119482666 (hardback) | ISBN 9781119482611 (adobe pdf) | ISBN 9781119482659 (epub)

Subjects: MESH: Sexual Dysfunction, Physiological-diagnosis | Sexual Dysfunction, Physiological-therapy | Sexual Dysfunctions, Psychological-therapy | Genital Diseases, Female | Pain | Pain Management

Classification: LCC RC560.S45 (print) | LCC RC560.S45 (ebook) | NLM WP 610 | DDC 618.1/7-dc23

LC record available at <https://lcn.loc.gov/2020024749>

LC ebook record available at <https://lcn.loc.gov/2020024750>

Cover Design: Wiley

Cover Image: © Chris Tefme/Shutterstock

## List of contributors

### **Jasmine Abdulcadir, MD, PD, FECSM**

Chief, Obstetric and Gynecological Emergency Unit  
Chief of Outpatient Clinic for Female Genital Mutilation  
Department of Woman, Child and Adolescent  
Geneva University Hospitals  
Geneva, Switzerland

### **Elizabeth Akincilar, MSPT**

Clinical Director  
Pelvic Health and Rehabilitation Centers  
Lexington, MA, USA

### **Meryl J. Alappattu, DPT, PhD**

Research Assistant Professor  
Department of Physical Therapy  
University of Florida  
Gainesville, FL, USA

### **Ariel Arbel, MD**

Department of Obstetrics and Gynecology  
Mayanei Hayeshua Medical Center  
Bnei Brak, Israel

### **Andrea M. Avondstondt, MD**

Female Pelvic Medicine and Reconstructive Surgery  
Atlantic Health System  
Morristown, NJ, USA

### **Gloria Bachmann, MD**

Associate Dean for Women's Health  
Department of Obstetrics, Gynecology and Reproductive  
Sciences  
Women's Health Institute  
Rutgers Robert Wood Johnson Medical School  
New Brunswick, NJ, USA

**Sarah Bedell, MD**

The Center for Vulvovaginal Disorders  
Washington, DC, USA

**Sophie Bergeron, PhD**

Professor  
Department of Psychology  
Université de Montréal  
Montréal, Québec, Canada

**Areta Bojko, BS**

George Washington University School of Medicine and  
Health Sciences  
Washington, DC, USA

**Jacob Bornstein**

Professor and Chairman, Department of Obstetrics and  
Gynecology, Galilee Medical Center and Azrieli Faculty of  
Medicine, Bar-Ilan University, Nahariya, Israel  
Chairman of the ISSVD Terminology Committee, Past  
President of ISSVD, Past chairman of IFCPC Nomenclature  
Committee

**Stéphanie Boyer, PhD**

Psychologist (Supervised Practice)  
Department of Psychology, Psychology Clinic  
Queen's University  
Kingston, Ontario, Canada

**Candace Brown, MSC, PharmD**

Professor Emeritus  
University of Tennessee Health Science Center  
College of Pharmacy  
Memphis, TN, USA

**Sarah Cigna, MSc, MD**

Associate Professor  
Department of Obstetrics and Gynecology  
George Washington University School of Medicine and